Table 4. Cumulative effects of the unfavorable genotypes on the prognosis of patients with advanced ESCC.
| ESCC patients withadvanced tumor (N = 334) | |||||
| Overallsurvival | Progression-freesurvival | ||||
| No. of unfavorablegenotypes | N | Adjusted HRs(95% CI) | p-value | Adjusted HRs(95% CI) | p-value |
| EGF:rs4444903+EGF:rs2237051 | |||||
| 0 | 155 | 1 | 1 | ||
| 1 | 45 | 0.95 (0.65−1.39) | 0.795 | 0.77 (0.53−1.18) | 0.169 |
| 2 | 134 | 1.41 (1.08−1.85) | 0.013 | 1.23 (0.96−1.58) | 0.107 |
| Trend | 1.18 (1.03−1.36) | 0.015 | 1.10 (0.97−1.25) | 0.140 | |
| EGF:rs4444903+VEGF:rs2010963 | |||||
| 0 | 144 | 1 | 1 | ||
| 1 | 162 | 1.40 (1.08−1.80) | 0.011 | 1.22 (0.96−1.55) | 0.107 |
| 2 | 28 | 1.70 (1.06–2.72) | 0.027 | 1.37 (0.88−2.13) | 0.164 |
| Trend | 1.34 (1.10−1.63) | 0.003 | 1.19 (0.99−1.43) | 0.063 | |
| EGF:rs2237051+VEGF:rs2010963 | |||||
| 0 | 154 | 1 | 1 | ||
| 1 | 153 | 1.43 (1.11−1.85) | 0.006 | 1.32 (1.03–1.68) | 0.027 |
| 2 | 27 | 1.74 (1.09−2.80) | 0.022 | 1.40 (0.89−2.18) | 0.144 |
| Trend | 1.37 (1.13−1.66) | 0.002 | 1.24 (1.03−1.48) | 0.022 | |
| EGF:rs4444903+EGF:rs2237051 +VEGF:rs2010963 | |||||
| 0 | 129 | 1 | 1 | ||
| 1 | 66 | 1.08 (0.77−1.51) | 0.654 | 0.91 (0.66−1.26) | 0.562 |
| 2 | 114 | 1.55 (1.16−2.08) | 0.003 | 1.34 (1.02−1.76) | 0.034 |
| 3 | 25 | 1.58 (0.96−2.61) | 0.075 | 1.25 (0.78−2.00) | 0.352 |
| Trend | 1.21 (1.07−1.37) | 0.002 | 1.10 (0.97−1.25) | 0.140 | |
| EGF:rs2237051+VEGF:rs2010963 +EGFR:rs2227983 | |||||
| 0 | 51 | 1 | 1 | ||
| 1 | 147 | 1.24 (0.86−7.79) | 0.247 | 1.26 (0.89−1.78) | 0.195 |
| 2 | 118 | 1.74 (1.19−2.53) | 0.004 | 1.66 (1.16−2.37) | 0.005 |
| 3 | 18 | 2.37 (1.25−4.50) | 0.008 | 1.52 (0.83−2.76) | 0.172 |
| Trend | 1.34 (1.14−1.57) | <0.001 | 1.23 (1.07−1.42) | 0.005 | |
| EGF:rs2237051+VEGF:rs2010963 +EGFR:rs2227983 +PIK3CA:rs6443624 | |||||
| 0 | 45 | 1 | 1 | ||
| 1 | 132 | 1.37 (0.93−2.03) | 0.115 | 1.35 (0.93−1.97) | 0.114 |
| 2 | 113 | 1.76 (1.18−2.63) | 0.006 | 1.80 (1.23–2.63) | 0.002 |
| 3 | 37 | 2.11 (1.27−3.50) | 0.004 | 1.63 (1.02−2.61) | 0.042 |
| 4 | 7 | 3.29 (1.36−7.96) | 0.008 | 1.68 (0.70−4.05) | 0.247 |
| Trend | 1.30 (1.14−1.48) | <0.001 | 1.19 (1.06−1.34) | 0.004 | |
| EGF:rs4444903+VEGF:rs2010963 +EGFR:rs2227983 | |||||
| 0 | 47 | 1 | 1 | ||
| 1 | 144 | 1.53 (1.05–2.21) | 0.026 | 1.46 (1.03−2.09) | 0.036 |
| 2 | 125 | 1.78 (1.22−2.60) | 0.003 | 1.62 (1.13−2.32) | 0.009 |
| 3 | 18 | 2.41 (1.26−4.59) | 0.008 | 1.64 (0.89−3.00) | 0.112 |
| Trend | 1.30 (1.11–1.51) | 0.001 | 1.19 (1.04−1.38) | 0.015 | |
| EGF:rs4444903+VEGF:rs2010963 +EGFR:rs2227983 +PIK3CA:rs6443624 | |||||
| 0 | 42 | 1 | 1 | ||
| 1 | 126 | 1.61 (1.08−2.40) | 0.020 | 1.49 (1.02−2.18) | 0.039 |
| 2 | 122 | 1.94 (1.30−2.89) | 0.001 | 1.87 (1.28−2.73) | 0.001 |
| 3 | 38 | 2.08 (1.24–3.47) | 0.005 | 1.59 (0.98−2.57) | 0.059 |
| 4 | 6 | 3.14 (1.20−8.19) | 0.020 | 1.57 (0.60−4.07) | 0.358 |
| Trend | 1.27 (1.12−1.45) | <0.001 | 1.17 (1.04−1.31) | 0.011 | |